Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors

NCT05983523 is registered in ClinicalTrials.gov with PharmaEngine as lead sponsor.

NCT NCT05983523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
Lead sponsor
PharmaEngine
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2024
Completion date
August 31, 2027
Enrollment
54 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor